IL271211B2 - Acetyl-leucine for use in treatment of migraine - Google Patents

Acetyl-leucine for use in treatment of migraine

Info

Publication number
IL271211B2
IL271211B2 IL271211A IL27121119A IL271211B2 IL 271211 B2 IL271211 B2 IL 271211B2 IL 271211 A IL271211 A IL 271211A IL 27121119 A IL27121119 A IL 27121119A IL 271211 B2 IL271211 B2 IL 271211B2
Authority
IL
Israel
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
IL271211A
Other languages
English (en)
Hebrew (he)
Other versions
IL271211A (en
IL271211B1 (en
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL271211(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of IL271211A publication Critical patent/IL271211A/en
Publication of IL271211B1 publication Critical patent/IL271211B1/en
Publication of IL271211B2 publication Critical patent/IL271211B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271211A 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine IL271211B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (3)

Publication Number Publication Date
IL271211A IL271211A (en) 2020-01-30
IL271211B1 IL271211B1 (en) 2023-09-01
IL271211B2 true IL271211B2 (en) 2024-01-01

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271211A IL271211B2 (en) 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine

Country Status (25)

Country Link
US (1) US11471434B2 (https=)
EP (1) EP3638370B1 (https=)
JP (1) JP7130739B2 (https=)
KR (1) KR102594130B1 (https=)
CN (1) CN111093772B (https=)
AU (1) AU2018284330B2 (https=)
CY (1) CY1123860T1 (https=)
DK (1) DK3638370T3 (https=)
ES (1) ES2847169T3 (https=)
GB (1) GB201709459D0 (https=)
HR (1) HRP20210108T1 (https=)
HU (1) HUE053089T2 (https=)
IL (1) IL271211B2 (https=)
LT (1) LT3638370T (https=)
MA (1) MA49396B1 (https=)
MD (1) MD3638370T2 (https=)
MX (1) MX387909B (https=)
PL (1) PL3638370T3 (https=)
PT (1) PT3638370T (https=)
RS (1) RS61481B1 (https=)
SG (1) SG11201912146RA (https=)
SI (1) SI3638370T1 (https=)
SM (1) SMT202100037T1 (https=)
WO (1) WO2018229738A1 (https=)
ZA (1) ZA201908087B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51836B1 (fr) * 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
WO2012064892A1 (en) * 2010-11-09 2012-05-18 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
DE602004017316D1 (de) * 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
SI1664016T1 (sl) * 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
PL1727801T3 (pl) * 2003-12-30 2009-08-31 Euro Celtique Sa Piperazyny użyteczne do leczenia bólu
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
AU2012293417A1 (en) * 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
ES2994242T3 (en) 2016-04-19 2025-02-05 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
HUE062729T2 (hu) 2017-03-28 2023-12-28 Intrabio Ltd Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra
IL273929B2 (en) 2017-10-18 2024-11-01 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
MA51836B1 (fr) 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
WO2012064892A1 (en) * 2010-11-09 2012-05-18 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Also Published As

Publication number Publication date
MA49396B1 (fr) 2021-03-31
DK3638370T3 (da) 2021-01-25
MA49396A (fr) 2020-04-22
KR20210013518A (ko) 2021-02-04
RU2020100475A3 (https=) 2021-10-22
CN111093772A (zh) 2020-05-01
HRP20210108T1 (hr) 2021-03-19
SI3638370T1 (sl) 2021-04-30
SMT202100037T1 (it) 2021-03-15
BR112019026660A2 (pt) 2020-07-14
ZA201908087B (en) 2024-11-27
AU2018284330B2 (en) 2024-03-14
IL271211A (en) 2020-01-30
US20200253905A1 (en) 2020-08-13
PT3638370T (pt) 2021-01-26
HUE053089T2 (hu) 2021-06-28
MD3638370T2 (ro) 2021-04-30
MX2019014784A (es) 2021-11-16
JP2020526575A (ja) 2020-08-31
SG11201912146RA (en) 2020-01-30
AU2018284330A1 (en) 2020-01-02
KR102594130B1 (ko) 2023-10-24
EP3638370A1 (en) 2020-04-22
JP7130739B2 (ja) 2022-09-05
GB201709459D0 (en) 2017-07-26
LT3638370T (lt) 2021-03-25
EP3638370B1 (en) 2020-11-11
CY1123860T1 (el) 2022-05-27
ES2847169T3 (es) 2021-08-02
PL3638370T3 (pl) 2021-05-17
IL271211B1 (en) 2023-09-01
RS61481B1 (sr) 2021-03-31
CN111093772B (zh) 2023-11-03
CA3067321A1 (en) 2018-12-20
MX387909B (es) 2025-03-19
RU2020100475A (ru) 2021-07-14
WO2018229738A1 (en) 2018-12-20
US11471434B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
US10842839B2 (en) Natural formulation for treating hangover
US20200147033A1 (en) Nutraceutical composition for pde4 inhibition, enhanced dopamine metabolism and long term potentiation
Ng et al. Potassium channel openers and prostacyclin play a crucial role in mediating the vasorelaxant activity of Gynura procumbens
CA2859062C (en) Ellagitannins rich extracts composition in sexual wellness
JP2020522487A (ja) ストレス障害のホルモンカスケードを調節する組成物および方法
WO2014175773A1 (ru) Средство для нормализации сна и биологических ритмов
US20060233892A1 (en) Topiramate compositions for treatment of headache
IL271211B2 (en) Acetyl-leucine for use in treatment of migraine
Rivera-García et al. The resurgence of hallucinogen drugs in clinical research
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
Woolf et al. Nondrug interventions for treatment of hypertension
Ortiz et al. Effect of a positive reinforcing stimulus on fear memory reconsolidation in ethanol withdrawn rats: Influence of d-cycloserine
US11484523B1 (en) Compositions for prevention and treatment of symptoms associated with alcohol consumption
MX2022012693A (es) Composicion que comprende metilfolato.
MX2024012638A (es) Composicion que comprende n-acetilcisteina, vitamina d y preferentemente glutation, usos de la misma, y composiciones farmaceuticas y nutraceuticas de los mismos
WO2025008516A3 (en) Indole derivatives with factor b inhibitory activity
JP2003286164A (ja) アセチルコリンエステラーゼ阻害剤
RU2572720C1 (ru) Комплексное антиникотиновое средство
CN103392882A (zh) 防贫血茶叶
Sönmez et al. Effects of oral supplementation of mint extract on muscle pain and blood lactate
Xu Magnesium Glycinate
US4609656A (en) Medical agent for improving and treating mental symptoms induced by cerebral disturbances
EP3071197B1 (en) Food for special medical purposes or food supplement formulation for treating hearing disturbances
WO2006087420A3 (en) A method for treating heart failure
CA2385774A1 (en) Composition to reduce food cravings and supress the appetite